Literature DB >> 32209474

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress.

Junko Murai1, Hongliang Zhang2, Lorinc Pongor2, Sai-Wen Tang2, Ukhyun Jo2, Fumiya Moribe2, Yixiao Ma3, Masaru Tomita3, Yves Pommier4.   

Abstract

Schlafen 11 (SLFN11) was recently discovered as a cellular restriction factor against replication stress. Here, we show that SLFN11 increases chromatin accessibility genome wide, prominently at active promoters in response to replication stress induced by the checkpoint kinase 1 (CHK1) inhibitor prexasertib or the topoisomerase I (TOP1) inhibitor camptothecin. Concomitantly, SLFN11 selectively activates cellular stress response pathways by inducing the transcription of the immediate early genes (IEGs), including JUN, FOS, EGR1, NFKB2, and ATF3, together with the cell cycle arrest genes CDKN1A (p21WAF1) and GADD45. Both chromatin remodeling and IEG activation require the putative ATPase and helicase activity of SLFN11, whereas canonical extrinsic IEG activation is SLFN11 independent. SLFN11-dependent IEG activation by camptothecin is also observed across 55 non-isogenic NCI-60 cell lines. We conclude that SLFN11 acts as a global regulator of chromatin structure and an intrinsic IEG activator with the potential to engage the innate immune activation in response to replicative stress. Published by Elsevier Inc.

Entities:  

Keywords:  ATR; CHK1; DNA damage; FOS; JUN; cell cycle checkpoint; chromatin; native immune response; replication stress; topoisomerase inhibitor

Mesh:

Substances:

Year:  2020        PMID: 32209474      PMCID: PMC7240837          DOI: 10.1016/j.celrep.2020.02.117

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  61 in total

1.  DNA-Targeted Precision Medicine; Have we Been Caught Sleeping?

Authors:  William C Reinhold; Anish Thomas; Yves Pommier
Journal:  Trends Cancer       Date:  2017-01

2.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities.

Authors:  Sven Heinz; Christopher Benner; Nathanael Spann; Eric Bertolino; Yin C Lin; Peter Laslo; Jason X Cheng; Cornelis Murre; Harinder Singh; Christopher K Glass
Journal:  Mol Cell       Date:  2010-05-28       Impact factor: 17.970

3.  BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.

Authors:  Florence Coussy; Rania El-Botty; Sophie Château-Joubert; Ahmed Dahmani; Elodie Montaudon; Sophie Leboucher; Ludivine Morisset; Pierre Painsec; Laura Sourd; Léa Huguet; Fariba Nemati; Jean-Luc Servely; Thibaut Larcher; Sophie Vacher; Adrien Briaux; Cécile Reyes; Philippe La Rosa; Georges Lucotte; Tatiana Popova; Pierre Foidart; Nor Eddine Sounni; Agnès Noel; Didier Decaudin; Laetitia Fuhrmann; Anne Salomon; Fabien Reyal; Christopher Mueller; Petra Ter Brugge; Jos Jonkers; Marie-France Poupon; Marc-Henri Stern; Ivan Bièche; Yves Pommier; Elisabetta Marangoni
Journal:  Sci Transl Med       Date:  2020-02-19       Impact factor: 17.956

4.  High-resolution, strand-specific R-loop mapping via S9.6-based DNA-RNA immunoprecipitation and high-throughput sequencing.

Authors:  Lionel A Sanz; Frédéric Chédin
Journal:  Nat Protoc       Date:  2019-05-03       Impact factor: 13.491

5.  Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position.

Authors:  Jason D Buenrostro; Paul G Giresi; Lisa C Zaba; Howard Y Chang; William J Greenleaf
Journal:  Nat Methods       Date:  2013-10-06       Impact factor: 28.547

6.  Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.

Authors:  Gabriele Zoppoli; Marie Regairaz; Elisabetta Leo; William C Reinhold; Sudhir Varma; Alberto Ballestrero; James H Doroshow; Yves Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

7.  Systematic identification of genomic markers of drug sensitivity in cancer cells.

Authors:  Mathew J Garnett; Elena J Edelman; Sonja J Heidorn; Chris D Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy J Milano; Graham R Bignell; Ah T Tam; Helen Davies; Jesse A Stevenson; Syd Barthorpe; Stephen R Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O'Brien; Jessica L Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam Butler; Hwan Geun Choi; Jae Won Chang; Jose Baselga; Ivan Stamenkovic; Jeffrey A Engelman; Sreenath V Sharma; Olivier Delattre; Julio Saez-Rodriguez; Nathanael S Gray; Jeffrey Settleman; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H Benes
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

8.  Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.

Authors:  Vanesa Nogales; William C Reinhold; Sudhir Varma; Anna Martinez-Cardus; Catia Moutinho; Sebastian Moran; Holger Heyn; Ana Sebio; Agusti Barnadas; Yves Pommier; Manel Esteller
Journal:  Oncotarget       Date:  2016-01-19

9.  BAMscale: quantification of next-generation sequencing peaks and generation of scaled coverage tracks.

Authors:  Lorinc S Pongor; Jacob M Gross; Roberto Vera Alvarez; Junko Murai; Sang-Min Jang; Hongliang Zhang; Christophe Redon; Haiqing Fu; Shar-Yin Huang; Bhushan Thakur; Adrian Baris; Leonardo Marino-Ramirez; David Landsman; Mirit I Aladjem; Yves Pommier
Journal:  Epigenetics Chromatin       Date:  2020-04-22       Impact factor: 4.954

10.  Model-based analysis of ChIP-Seq (MACS).

Authors:  Yong Zhang; Tao Liu; Clifford A Meyer; Jérôme Eeckhoute; David S Johnson; Bradley E Bernstein; Chad Nusbaum; Richard M Myers; Myles Brown; Wei Li; X Shirley Liu
Journal:  Genome Biol       Date:  2008-09-17       Impact factor: 13.583

View more
  15 in total

1.  SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy.

Authors:  Ahmed Adham Raafat Elsayed; Sarmad Al-Marsoummi; Emilie E Vomhof-Dekrey; Marc D Basson
Journal:  Cancer Genomics Proteomics       Date:  2022 May-Jun       Impact factor: 4.069

2.  Modulation of viral replication, apoptosis and antiviral response by induction and mutual regulation of EGR and AP-1 family genes during coronavirus infection.

Authors:  Lixia Yuan; To Sing Fung; Jiawen He; Rui Ai Chen; Ding Xiang Liu
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

3.  Transcriptional reprogramming by oxidative stress occurs within a predefined chromatin accessibility landscape.

Authors:  Daniel C Levings; Sarah E Lacher; Juan Palacios-Moreno; Matthew Slattery
Journal:  Free Radic Biol Med       Date:  2021-05-13       Impact factor: 8.101

4.  SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243.

Authors:  Yasuhisa Murai; Ukhyun Jo; Naoko Takebe; Yves Pommier; Junko Murai; Lisa M Jenkins; Shar-Yin N Huang; Sirisha Chakka; Lu Chen; Ken Cheng; Shinsaku Fukuda
Journal:  Cancer Res       Date:  2021-04-16       Impact factor: 13.312

5.  Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.

Authors:  Fumiya Moribe; Momoko Nishikori; Tsuyoshi Takashima; Daiki Taniyama; Nobuyuki Onishi; Hiroshi Arima; Hiroyuki Sasanuma; Remi Akagawa; Fathi Elloumi; Shunichi Takeda; Yves Pommier; Eiichi Morii; Akifumi Takaori-Kondo; Junko Murai
Journal:  PLoS One       Date:  2021-01-29       Impact factor: 3.240

6.  SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.

Authors:  Ukhyun Jo; Yasuhisa Murai; Sirisha Chakka; Lu Chen; Ken Cheng; Junko Murai; Liton Kumar Saha; Lisa M Miller Jenkins; Yves Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

7.  Structural and biochemical characterization of human Schlafen 5.

Authors:  Felix J Metzner; Elisabeth Huber; Karl-Peter Hopfner; Katja Lammens
Journal:  Nucleic Acids Res       Date:  2022-01-25       Impact factor: 16.971

8.  Topoisomerase I inhibition and peripheral nerve injury induce DNA breaks and ATF3-associated axon regeneration in sensory neurons.

Authors:  Yung-Chih Cheng; Andrew Snavely; Lee B Barrett; Xuefei Zhang; Crystal Herman; Devlin J Frost; Priscilla Riva; Ivan Tochitsky; Riki Kawaguchi; Bhagat Singh; Jelena Ivanis; Eric A Huebner; Anthony Arvanites; Vatsal Oza; Lance Davidow; Rie Maeda; Miyuki Sakuma; Alyssa Grantham; Qing Wang; Amelia N Chang; Kathleen Pfaff; Michael Costigan; Giovanni Coppola; Lee L Rubin; Bjoern Schwer; Frederick W Alt; Clifford J Woolf
Journal:  Cell Rep       Date:  2021-09-07       Impact factor: 9.423

9.  SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.

Authors:  Claudia Winkler; Matthew King; Julie Berthe; Domenico Ferraioli; Anna Garuti; Federica Grillo; Jaime Rodriguez-Canales; Lorenzo Ferrando; Nicolas Chopin; Isabelle Ray-Coquard; Oona Delpuech; Darawan Rinchai; Davide Bedognetti; Alberto Ballestrero; Elisabetta Leo; Gabriele Zoppoli
Journal:  JCI Insight       Date:  2021-09-22

Review 10.  A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers.

Authors:  Bingnan Zhang; Kavya Ramkumar; Robert John Cardnell; Carl Michael Gay; C Allison Stewart; Wei-Lien Wang; Junya Fujimoto; Ignacio I Wistuba; Lauren Averett Byers
Journal:  Br J Cancer       Date:  2021-07-22       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.